Skip to main content
Equibles
MRMD logo

MRMD · Marimed Inc. · Documents

Track MRMD — free

Use MRMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MRMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.08 +0.00 (+3.22%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$30.99M
Shares
403.04M
Volume · Nov 12 155.66K Avg daily vol (3M) 772.65K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $159.83M up 1.3% 10-K filed Mar 12, 2026 Quarterly report FY2026 Q2 Revenue $41.93M up 6.1% 10-Q filed Aug 13, 2026 Latest results New Financial results 8-K filed Nov 12, 2026 Earnings call New Q3 2026 earnings call Held Nov 12, 2026
2026
Oct 29
Current report 8-K Events of Oct 28
Shareholder vote results, Other events

On October 28, 2026, MariMed Inc. stockholders approved a reverse stock split at a ratio of not less than one-for-fifty and not more than one-for-one hundred; the board retains discretion over implementation, final ratio, or abandonment.

Sep 23
Current report 8-K
Other events

MariMed will ask stockholders at an October 28, 2026 meeting to approve a proposed reverse stock split ranging from one for fifty to one for one-hundred, intended to support a potential U.S. national securities exchange listing.

Sep 22
Proxy statement DEF 14A Meeting Oct 28, 2026
Proxy statement

MariMed Inc. asks stockholders to authorize a reverse stock split ranging from one-for-fifty (1-for-50) to one-for-one hundred (1-for-100), with the board authorized to select the ratio or abandon the split; the board recommends approval.

Read from the first part of this long document
Sep 11
Proxy statement PRE 14A Meeting Oct 28, 2026
Proxy statement AI summary on its way
Aug 13
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $41.93M ▲ 6.1% Net loss $3.59M Diluted EPS -$0.01
May 14
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $39.48M ▲ 4.2% Net loss $3.79M Diluted EPS -$0.01
Apr 23
Proxy statement DEF 14A Meeting Jun 4, 2026
Proxy statement AI summary on its way
Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $159.83M ▲ 1.3% Net loss $14.48M Diluted EPS -$0.04
2025
Mar 6
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $157.96M ▲ 6.3% Net loss $12.16M Diluted EPS -$0.03
2024
Mar 7
Annual report 10-K FY2023, ended Dec 31
Annual report for FY2023
Revenue $148.6M ▲ 10.9% Net loss $16.03M Diluted EPS -$0.04
2023
Showing 1–50 of 104 documents
Key facts CIK 1522767 CUSIP 56782V107 13F (30d) 1 filings 1 filers Visit website Investor relations